Why does my product say “WARNING: This product contains lead, a chemical known to the State of California to birth defects or other reproductive harm”?

This statement is legal text required by a California law called “Proposition 65.” Proposition 65 applies to over 900 different man-made and naturally occurring chemicals and substances. For example, “aspirin” is on the Proposition 65 list and both man-made and naturally occurring metals are on the list.

Why do your competitors’ products not have a warning?

All companies that sell products into California have to comply with Proposition 65. We cannot comment on the reasons why other companies do not to provide a Proposition 65 warning.

What is Proposition 65?

Proposition 65 is a California “right to know” law that requires companies to tell consumers if their products, including food, contain or cause an exposure to one or more of the chemicals on the State’s list.

Does this product cause reproductive harm?

All of our products are tested for safety. Proposition 65 warnings are required when the amount of a chemical in a daily exposure is anything more than 1/1000th of the amount that scientific studies have documented shows no observable effect on reproductive health.

Connect

Join Our Newsletter

* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

Information on the AG1 site is provided for informational purposes only. It is not meant to substitute for medical advice from your physician or other medical professional. You should not use the information contained herein for diagnosing or treating a health problem or disease, or prescribing any medication. Carefully read all product documentation. If you have or suspect that you have a medical problem, promptly contact your regular health care provider.

** Offer valid for first time subscribers only.

Actual Packaging May Vary

  1. In a triple-blind, randomized, placebo-controlled parallel-designed clinical trial evaluating nutrient biomarkers and microbiome shifts in 105 healthy adults ages 20-59 over the course of 12 weeks.
  2. In a double-blind, randomized, placebo-controlled 2-week crossover clinical trial assessing nutrient gaps and microbiome shifts in 20 active adults ages 19-37.
  3. In a double-blind, randomized, placebo-controlled 2-week crossover clinical trial assessing nutrient gaps and microbiome assessments of 40 healthy adults with occasional GI distress ages 26-59 over the course of 4 weeks.
  4. In a double-blind, randomized, placebo-controlled crossover clinical trial assessing nutrient gaps and bioavailability in 16 healthy adults ages 18-42 over the course of 8 hours.
  5. In a third-party, single-arm, closed label interventional study of 104 healthy adults ages 25-9 assessing self-perceived efficacy of AG1 Next Gen over 3 months.